BIOMED-LUBLIN WYT.SUR.
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 5… Read more
BIOMED-LUBLIN WYT.SUR. (6NQ) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, BIOMED-LUBLIN WYT.SUR. (6NQ) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
BIOMED-LUBLIN WYT.SUR. - Net Assets Trend (None–None)
This chart illustrates how BIOMED-LUBLIN WYT.SUR.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BIOMED-LUBLIN WYT.SUR. (None–None)
The table below shows the annual net assets of BIOMED-LUBLIN WYT.SUR. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to BIOMED-LUBLIN WYT.SUR.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
BIOMED-LUBLIN WYT.SUR. Competitors by Market Cap
The table below lists competitors of BIOMED-LUBLIN WYT.SUR. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BANGO PLC LS-20
F:B1O
|
$35.58 Million |
|
Nyrada Inc
AU:NYR
|
$35.58 Million |
|
Vente Unique.com
PA:ALVU
|
$35.59 Million |
|
Caladrius Biosciences Inc.
LSE:0HS8
|
$35.60 Million |
|
Jetpak Top Holding AB
ST:JETPAK
|
$35.56 Million |
|
Optomed PLC
HE:OPTOMED
|
$35.53 Million |
|
Lisata Therapeutics Inc.
NASDAQ:LSTA
|
$35.53 Million |
|
Orient Technologies Limited
NSE:ORIENTTECH
|
$35.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BIOMED-LUBLIN WYT.SUR.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares BIOMED-LUBLIN WYT.SUR.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently BIOMED-LUBLIN WYT.SUR. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares BIOMED-LUBLIN WYT.SUR.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BIOMED-LUBLIN WYT.SUR. (6NQ) | €- | N/A | N/A | $35.57 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |